TY - JOUR
T1 - Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts
AU - Estrov, Zeev
AU - Meir, Roza
AU - Barak, Yigal
AU - Zaizov, Rina
AU - Zadik, Zvi
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1991
Y1 - 1991
N2 - As the number of long-term survivors of childhood leukemia increases, growth retardation has emerged as a significant complication. Treatment of these children with growth hormone (GH) has been suggested and sporadically implemented. We, therefore, studied the effect of human GH (hGH) and its by-product insulin-like growth factor-1 (IGF-1) on the growth of leukemic cells in vitro. Under serum-free conditions hGH and IGF-1 induced a significant dose-dependent proliferative effect on promyelocytic leukemia (HL60) and Burkitt's lymphoma (Daudi) cell lines. Anti-hGH antibodies negated the stimulatory effect of hGH and anti-IGF-1 serum abrogated the growth-promoting effect enhanced by IGF-1. Similar statistically significant stimulatory properties were found when freshly obtained marrow cells from four of five acute lympho-blastic leukemia (ALL) of childhood and four acute myelogenous leukemia (AML) patients were studied in ALL and AML blast-cell clonogenic assays. ALL colonies increased numerically by 72% (P < .025) and AML colonies by 92% (P < .01 ) in the presence of hGH at concentrations of 2.5 × 102 and 3.0 × 102 ng/mL, respectively. IGF-1 stimulated ALL and AML blast-colony growth at concentrations ranging from 0.05 to 0.5 ng/mL by up to 105% (P < .025) and 65% (P < .03), respectively. Our in vitro data suggest that circulating hGH and IGF-1 may promote leukemic blast cell replication in vivo, and the supplemental administration of hGH to leukemia patients in remission must be carefully monitored for early relapse.
AB - As the number of long-term survivors of childhood leukemia increases, growth retardation has emerged as a significant complication. Treatment of these children with growth hormone (GH) has been suggested and sporadically implemented. We, therefore, studied the effect of human GH (hGH) and its by-product insulin-like growth factor-1 (IGF-1) on the growth of leukemic cells in vitro. Under serum-free conditions hGH and IGF-1 induced a significant dose-dependent proliferative effect on promyelocytic leukemia (HL60) and Burkitt's lymphoma (Daudi) cell lines. Anti-hGH antibodies negated the stimulatory effect of hGH and anti-IGF-1 serum abrogated the growth-promoting effect enhanced by IGF-1. Similar statistically significant stimulatory properties were found when freshly obtained marrow cells from four of five acute lympho-blastic leukemia (ALL) of childhood and four acute myelogenous leukemia (AML) patients were studied in ALL and AML blast-cell clonogenic assays. ALL colonies increased numerically by 72% (P < .025) and AML colonies by 92% (P < .01 ) in the presence of hGH at concentrations of 2.5 × 102 and 3.0 × 102 ng/mL, respectively. IGF-1 stimulated ALL and AML blast-colony growth at concentrations ranging from 0.05 to 0.5 ng/mL by up to 105% (P < .025) and 65% (P < .03), respectively. Our in vitro data suggest that circulating hGH and IGF-1 may promote leukemic blast cell replication in vivo, and the supplemental administration of hGH to leukemia patients in remission must be carefully monitored for early relapse.
UR - http://www.scopus.com/inward/record.url?scp=0026030103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026030103&partnerID=8YFLogxK
U2 - 10.1200/JCO.1991.9.3.394
DO - 10.1200/JCO.1991.9.3.394
M3 - Article
C2 - 1999709
AN - SCOPUS:0026030103
SN - 0732-183X
VL - 9
SP - 394
EP - 399
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -